Heidelberg Pharma AG/ DE000A11QVV0 /
2024-05-16 7:57:06 AM | Chg. -0.0100 | Volume | Bid9:58:00 PM | Ask9:58:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
2.9500EUR | -0.34% | - Turnover: - |
2.9400Bid Size: 1,050 | 2.9900Ask Size: 1,050 | 101.5 mill.EUR | 0.00% | - |
GlobeNewswire
2017-11-16
Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%
GlobeNewswire
2007-11-12
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2007-11-12
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2007-02-05
Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis
GlobeNewswire
2006-10-09
Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients